Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study

Status Active, not recruiting

Clinical Trial Summary

The Investigators hypothesise that asthma is not a single disease, but a syndrome resulting from several distinct underlying disease processes known as endotypes. There are approximately 30,000 genes in humans, and each gene is responsible for the production of a particular protein. Using a technique called "whole genome expression profiling" The Investigators have undertaken a small study looking at the activity of all 30,000 genes in the airway tissue of people with asthma. This work has identified 3 mutually exclusive distinct molecular patterns (endotypes) of severe asthma and has identified other potentially important molecular targets (manuscripts in preparation). In particular,the Investigators have found that 25-50% of patients have asthma associated with the activity of proteins called Th2 cytokines (Th2-high asthma). New treatments are in development that target this pathway. However, the Investigators do not know what is driving severe asthma in patients who do not express these Th2 cytokines. The aim of this study is to investigate in more detail the molecular mechanisms driving severe asthma in patients who do not express Th2 cytokines (Th2-low asthma), so that the Investigators can identify new targets for treatment in this group. To do this the Investigators will collect airway tissue via a telescope (bronchoscope), and analyse gene and protein expression in the tissue. The Investigators will then compare the molecular activity between patients with Th2-high and Th2-low asthma, and healthy control subjects (data obtained from a parallel study).

Clinical Trial Description

Asthma is a very common disorder which causes a great deal of distress for patients, and occasionally results in premature death. Approximately 10% of people with asthma have severe disease which is not helped by current treatments; The Investigators need to find new treatments for these patients urgently. Patients with asthma are not all the same, but have distinct features which characterise their asthma.The Investigators therefore hypothesise that asthma is not a single disease, but a syndrome resulting from several distinct underlying disease processes known as endotypes. There are approximately 30,000 genes in humans, and each gene is responsible for the production of a particular protein. Using a technique called "whole genome expression profiling" The Investigators have undertaken a small study looking at the activity of all 30,000 genes in the airway tissue of people with asthma. This work has identified 3 mutually exclusive distinct molecular patterns (endotypes) of severe asthma and has identified other potentially important molecular targets (manuscripts in preparation). In particular, the Investigators have found that 25-50% of patients have asthma associated with the activity of proteins called Th2 cytokines (Th2-high asthma). New treatments are in development that target this pathway. However, the Investigators do not know what is driving severe asthma in patients who do not express these Th2 cytokines. The aim of this study is to investigate in more detail the molecular mechanisms driving severe asthma in patients who do not express Th2 cytokines (Th2-low asthma), so that the Investigators can identify new targets for treatment in this group. To do this the Investigators will collect airway tissue via a telescope (bronchoscope), and analyse gene and protein expression in the tissue. The Investigators will then compare the molecular activity between patients with Th2-high and Th2-low asthma, and healthy control subjects (data obtained from a parallel study). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02883530
Study type	Observational
Source	University of Leicester
Contact
Status	Active, not recruiting
Phase
Start date	September 26, 2016
Completion date	October 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02513160` - Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma	Phase 3
Completed	`NCT02003521` - Impact of Lung Flute Therapy on Asthma	N/A
Completed	`NCT01253603` - Efficacy, Safety, and Pharmacokinetics of QAW039	Phase 2
Completed	`NCT01845025` - Study of Safety of Foradil in Patients With Persistent Asthma	Phase 4
Not yet recruiting	`NCT02053402` - Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital	Phase 4
Completed	`NCT01156844` - Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol	Phase 2
Completed	`NCT01078688` - Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma	N/A
Completed	`NCT02176694` - Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care	N/A
Completed	`NCT02026336` - E-nose and Inflammatory Asthma Phenotypes	N/A
Withdrawn	`NCT04271839` - Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients	Phase 4
Active, not recruiting	`NCT04480242` - Asthma Research in Children and Adolescents
Completed	`NCT02175771` - Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma	Phase 3
Completed	`NCT01147510` - Asthma Control in Elderly Patients With Montelukast	Phase 4
Completed	`NCT03541187` - Cockroach Immunotherapy in Children and Adolescents	Phase 2
Completed	`NCT02040779` - A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma	Phase 3
Active, not recruiting	`NCT05843045` - Indoor Air Quality Asthma Study: The Effect of Indoor Air Quality and Mitigation of Same on Persistent Asthma	N/A